Home > Research Areas > Neurological Disease > Alzheimer Disease
Cat. No. Product name CAS No.
DC11019 ASP3662 Featured

ASP3662 is a potent, selective, CNS-penetrable and orally active inhibitor of 11β-HSD1 with Ki of 5.3, 2.6 and 23 nM for human, mouse and rat 11β-HSD1, does not inhibit human 11β-HSD2 at 30 uM.

1204178-50-6
DCS-019 (-)-Huperzine A

>98%,Standard References

102518-79-6
DCJ-030 Galanthamine

>98%,Standard References

357-70-0
DC11301 ALZ-801 Featured

ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease.

1034190-08-3
DC9946 Lanabecestat(AZD3293,LY-3314814)

AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease.

1383982-64-6
DC8400 AZD3839 Featured

AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

1227163-84-9
DC8338 Azeliragon(PF-04494700,TTP488) Featured

Azeliragon is an oral, small-molecule inhibitor of RAGE.

603148-36-3
DC11105 Umibecestat Featured

beta-secretase inhibitor.

1387560-01-1
DC11389 BI 409306 Featured

BI 409306 is an inhibitor of phosphodisterase 9A(PDE9A).

1189767-28-9
DC3114 Avagacestat (BMS-708163) Featured

BMS-708163 is a potent, selective γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, respectively.

1146699-66-2
DC11038 Bryostatin 1 Featured

Bryostatin 1 (NSC 339555) is a macrocyclic lactone derived from a marine invertebrate, fuctions as an activator of PKC with high binding affinity (Ki=1.35 nM).

83314-01-6
DC10506 CPHPC(Miridesap) Featured

CPHPC(GSK2315698,Miridesap) is a divalent crosslinker of SAP that causes rapid depletion of circulating SAP via hepatic clearance.

224624-80-0
DC8277 E-2012 Featured

E 2012 is a potent γ-secretase modulator.

870843-42-8
DC11551 Elenbecestat Featured

Elenbecestat (E2609) is a novel potent, oral BACE1 inhibitor for treatment of Alzheimer's disease..

1388149-39-0
DC10490 GIBH-130 Featured

GIBH-130 is a novel inhibitor of neuroinflammation effective in Alzheimer’s disease models.

1252608-59-5
DC5061 GYKI 52466 dihydrochloride

GYKI 52466 dihydrochloride is a selective non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 μM for AMPA- , kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant.

102771-26-6
DC9329 (±)-Huperzine A

Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).

120786-18-7
DC5180 LY2811376 Featured

LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM.

1194044-20-6
DC5053 LY2886721 Featured

LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease.

1262036-50-9
DC5036 LY-411575 Featured

LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with withIC50 of 0.39 nM.

209984-57-6
DC9901 Verubecestat (MK-8931) Featured

MK-8931 is a BACE1 inhibitor. MK-8931 binds significantly to β-secretase.

1286770-55-5
DC11247 Nelonicline Featured

Nelonicline (ABT-126) is a potent, selective α7 nicotinic receptor (nAChR) partial agonist for the treatment of cognitive impairment with schizophrenia..

1026134-63-3
Page 1 / Total 2 FirstPrevNextLastGoto